Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation

Despite the recent introduction of mold-active antifungal prophylaxis (MAP), breakthrough invasive fungal infections (b-IFI) still represent a possible complication and a cause of morbidity and mortality in hematological patients and allogeneic hematopoietic stem-cell transplantation recipients (HSCT). Data on incidence and type of b-IFI are limited, although they are mainly caused by non-fumigatus Aspergillus and non-Aspergillus molds and seem to depend on specific antifungal prophylaxis and patients’ characteristics. Herein, we described the clinical presentation and management of two cases of rare b-IFI which recently occurred at our institution in patients undergoing HSCT and receiving MAP. The management of b-IFI is challenging due to the lack of data from prospective trials and high mortality rates. A thorough analysis of risk factors, ongoing antifungal prophylaxis, predisposing conditions and local epidemiology should drive the choice of antifungal treatments. Early broad-spectrum preemptive therapy with a lipid formulation of amphotericin-B, in combination with a different mold-active azole plus/minus terbinafine, is advisable. The therapy would cover against rare azole-susceptible and -resistant fungal strains, as well as atypical sites of infections. An aggressive diagnostic work-up is recommended for species identification and subsequent targeted therapy.

[1]  P. Woo,et al.  Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. , 2021, The Lancet. Infectious diseases.

[2]  E. Poeschla,et al.  Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents , 2020, Open forum infectious diseases.

[3]  L. Pagano Faculty Opinions recommendation of A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020 .

[4]  Yeon Joo Lee,et al.  A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  An Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds , 2020, Case Medical Research.

[6]  M. Christner,et al.  Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  C. Kauffman,et al.  Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia , 2020, Mycopathologia.

[8]  H. Badali,et al.  Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.

[9]  L. Pagano,et al.  Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. , 2019, Medical mycology.

[10]  D. Pakstis,et al.  Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope® , 2019, Critical reviews in microbiology.

[11]  P. Ljungman,et al.  European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.

[12]  D. Kontoyiannis,et al.  Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Breilh,et al.  Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis , 2018, Oncotarget.

[14]  A. Ibrahim,et al.  Challenges in the diagnosis and treatment of mucormycosis. , 2018, Medical mycology.

[15]  S. Ranque,et al.  Scedosporium and Lomentospora: an updated overview of underrated opportunists. , 2018, Medical mycology.

[16]  L. Pagano,et al.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.

[17]  J. Perfect,et al.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.

[18]  M. Cuenca‐Estrella,et al.  Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  P. Chiusolo,et al.  Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  L. Pagano,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  L. Pagano,et al.  ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  P. Hamal,et al.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  L. Pagano,et al.  Scedosporiosis in patients with acute leukemia: a retrospective multicenter report , 2008, Haematologica.

[25]  B. Thiers Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[26]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[27]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[28]  W. Leisenring,et al.  Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Nina Singh,et al.  Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  O. Sezer,et al.  Mucormycoses , 2001, Mycoses.

[31]  A. Favero,et al.  Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. , 2001, Haematologica.